drugset / Trial / NCT06581198

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198

Phase 2 Recruiting 179 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).

Timeline

Start
2024-09-04
Primary completion
2028-02-14
Completion
2032-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject rapcabtagene autoleucel Cell therapy